• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, July 6, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

CENTECH’s Propulsion Program will help Innodem Neurosciences succeed globally

Bioengineer by Bioengineer
May 18, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Innodem

CENTECH, a Montreal-based technology incubator, announced earlier that it has selected a company founded by Dr. Etienne de Villers-Sidani for its Propulsion Program, which helps the most innovative start-ups move from the initial development phase to commercializing their products and services on the international market. Dr. de Villers-Sidani is a researcher and neurologist at Montreal Neurological Institute and Hospital (The Neuro) and member of the Center for Research on Brain, Language and Music (CRBLM). Dr. de Villers-Sidani's company, Innodem Neurosciences, has developed a patent-pending mobile application that will improve the effectiveness and quality of life and care of patients with neurological problems. Innodem's eye-tracking technology for mobile devices allows patients that cannot speak because of paralysis (ALS, stroke, etc.) or intubation (intensive care) to communicate by simply gazing at various images on a tablet or smartphone linked to the patient's pre-recorded or synthetic text-to-speech voice messages. This innovation is meant to improve the less efficient message boards and standard of care that rely on third-parties rather than being patient-centric. Communication with several types of neurological patients is often only possible by tracking eye movements. Innodem's application can anonymously track these gaze patterns because its technology uses image-processing algorithms to capture eye movements with high precision using standard cameras found on most off-the-shelf electronic tablets and smartphones. The company believes that as more people use the app, the AI back-end that it is developing will help it launch other apps to assist the medical and pharmaceutical industry make better diagnostics for neurological diseases. Metrics can also be extracted for diagnosis or to follow illness progression.

Innodem's current competitors require the use of proprietary hardware such as infrared cameras, reducing the availability and increasing the cost of such technology. Currently, eye-tracking systems designed for paralyzed individuals cost several thousand dollars, making them unaffordable for cost-sensitive healthcare institutions and most patients. Innodem's technology on the other hand will be software-based and thus very affordable.

Innodem Neuroscience technology is a result of Dr. de Villers-Sidani's work at The Neuro developing novel therapeutic strategies that can improve cognitive function, communication and quality of life in patients suffering from various neurological conditions, including neurodegenerative disorders and strokes.

CENTECH's Propulsion Program will come with a $10,000 award and access to leading edge infrastructure, equipment and software, mentorship and networking opportunities.

"With Innodem and the arrival of Dr. Villers-Sidani's team, CENTECH will concretize its vision of bringing together a concentration of the best Med Tech start-ups under one roof," explained Richard Chénier, CENTECH's Director General. "We are developing a true community of expertise in this field, here in Montréal, thanks to best of class institution such as The Neuro."

###

About CENTECH

Created in 1996 by the École de Technologie Supérieure, and located in the heart of Montréal's Quartier de l'innovation, CENTECH is a start-up company launcher dedicated to technological tools and other advanced technologies with high growth potential. Recognized by UBI (University Business Network) as one of the world's most effective accelerators, CENTECH acts as a veritable growth machine. It has created one of the greatest densities of high-level tech entrepreneurs in Canada.

About The Montreal Neurological Institute and Hospital

The Montreal Neurological Institute and Hospital – The Neuro – is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical centre in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world's top minds makes The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. In 2016, The Neuro became the first institute in the world to fully embrace the Open Science philosophy, creating the Tanenbaum Open Science Institute. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre. For more information, please visit http://www.theneuro.ca

Media Contact

Shawn Hayward
[email protected]
514-398-3376
@McGillU

http://www.mcgill.ca

Original Source

http://www.mcgill.ca/neuro/channels/news/centechs-propulsion-program-will-help-innodem-neurosciences-succeed-globally-287234

Share12Tweet8Share2ShareShareShare2

Related Posts

Flame retardant BDE-209 targets molecularly linked to ulcerative colitis

July 6, 2026

Kidney transplant outcomes in older adults studied by German researchers

July 6, 2026

Salmonella protein SopB curbs early inflammation to slow disease progression

July 6, 2026

Multi-metal cooperation drives lung cancer chemoresistance, reversed by MiADMSA

July 6, 2026
Please login to join discussion

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Flame retardant BDE-209 targets molecularly linked to ulcerative colitis

Ultra-high frequency particle impacts mimic rockbursts to shatter hard rock

Kidney transplant outcomes in older adults studied by German researchers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 83 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.